Skip to main content
Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Vascular Dysfunction in Horses with Endocrinopathic Laminitis

  • Ruth A. Morgan ,

    Affiliations University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom, Royal (Dick) School of Veterinary Studies, University of Edinburgh, Midlothian, United Kingdom

  • John A. Keen,

    Affiliation Royal (Dick) School of Veterinary Studies, University of Edinburgh, Midlothian, United Kingdom

  • Brian R. Walker,

    Affiliation University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom

  • Patrick W. F. Hadoke

    Affiliation University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom


Endocrinopathic laminitis (EL) is a vascular condition of the equine hoof resulting in severe lameness with both welfare and economic implications. EL occurs in association with equine metabolic syndrome and equine Cushing’s disease. Vascular dysfunction, most commonly due to endothelial dysfunction, is associated with cardiovascular risk in people with metabolic syndrome and Cushing’s syndrome. We tested the hypothesis that horses with EL have vascular, specifically endothelial, dysfunction. Healthy horses (n = 6) and horses with EL (n = 6) destined for euthanasia were recruited. We studied vessels from the hooves (laminar artery, laminar vein) and the facial skin (facial skin arteries) by small vessel wire myography. The response to vasoconstrictors phenylephrine (10−9–10-5M) and 5-hydroxytryptamine (5HT; 10−9–10-5M) and the vasodilator acetylcholine (10−9–10-5M) was determined. In comparison with healthy controls, acetylcholine-induced relaxation was dramatically reduced in all intact vessels from horses with EL (% relaxation of healthy laminar arteries 323.5 ± 94.1% v EL 90.8 ± 4.4%, P = 0.01, laminar veins 129.4 ± 14.8% v EL 71.2 ± 4.1%, P = 0.005 and facial skin arteries 182.0 ± 40.7% v EL 91.4 ± 4.5%, P = 0.01). In addition, contractile responses to phenylephrine and 5HT were increased in intact laminar veins from horses with EL compared with healthy horses; these differences were endothelium-independent. Sensitivity to phenylephrine was reduced in intact laminar arteries (P = 0.006) and veins (P = 0.009) from horses with EL. Horses with EL exhibit significant vascular dysfunction in laminar vessels and in facial skin arteries. The systemic nature of the abnormalities suggest this dysfunction is associated with the underlying endocrinopathy and not local changes to the hoof.


Laminitis is a crippling disease of the horse’s hoof resulting from mechanical failure of the laminar tissue, an interdigitating fibrous structure which suspends the distal phalanx within the hoof capsule. Failure of this tissue results in rotation and sinking of the distal phalanx causing acute pain when the horse bears weight. This condition is of huge clinical significance affecting up to 34% of horses [1] and commonly necessitates euthanasia on welfare grounds. Up to 90% of laminitis cases occur in association with the common conditions of Equine Cushing’s Disease (Pituitary Pars Intermedia Dysfunction, PPID) or Equine Metabolic Syndrome (EMS); so called endocrinopathic laminitis (EL) [2]. The causal mechanisms that link these endocrine disturbances with laminitis are unknown but since dysregulation of the blood flow to the laminae in both acute sepsis-related laminitis [3] and in chronic forms [4, 5] has been demonstrated, vascular dysfunction may represent a feasible link.

Human endocrine disturbances, such as Cushing’s syndrome and metabolic syndrome, are associated with systemic vascular dysfunction contributing to increased cardiovascular risk in these patients [68]. Endothelial dysfunction, manifest most commonly by failure of endothelial-dependent vasodilation, is a common finding in patients with atherosclerosis secondary to these conditions [9]. Given the complexities of these endocrine disturbances, it is difficult to determine causality particularly when likely candidates for altering vascular function such as insulin resistance, hyperinsulinaemia, cortisol dysregulation, inflammation and obesity often occur simultaneously [10]. Endothelial dysfunction is the most common vascular dysfunction associated with hyperinsulinaemia and insulin resistance in humans [11]. Insulin resistance is, independent of other risk factors, correlated with cardiovascular risk in humans [12, 13], as is obesity, specifically visceral body fat content [14] [15, 16]. In healthy human patients glucocorticoids inhibit cholinergic vasodilation [17] and potentiate the action of vasoconstrictors [18]. Endogenous or exogenous hypercortisolaemia is associated with endothelial dysfunction and increased risk of cardiovascular disease in human patients [19] [20] [21]. Numerous rodent, rabbit and canine models of diabetes, obesity and Cushing’s syndrome have been used to demonstrate endothelial dysfunction but there are little data on naturally occurring endocrine disease in other species [22, 23]. Pituitary Pars Intermedia Dysfunction in horses, is due to adenomatous or hyperplastic dysfunction of the pars intermedia of the pituitary and unlike other species is not associated with hypercortisolaemia.

As in humans, horses with metabolic syndrome or PPID often have multiple risk factors that are associated with endothelial dysfunction in humans. Insulin resistance and hyperinsulinaemia occur commonly in horses with EMS and PPID [24]. Horses with PPID are more likely to have laminitis if they are hyperinsulinaemic [25] and hyperinsulinaemia is a poor prognostic indicator for recovery from laminitis [26]. There is evidence that high dose insulin infusion can induce laminitis in otherwise healthy horses but the vascular function of these horses have not been investigated [27]. Generalised and regional adiposity and weight gain are independent predictors of laminitis risk [28, 29]. Exogenous glucocorticoid administration is, anecdotally, associated with the development of laminitis though convincing data of a causal relationship is lacking [30]. Cortisol has been shown to potentiate the response to vasoconstrictors in ex vivo studies of horses [31]. Treatments for laminitis have often empirically targeted a presumed vascular dysfunction with limited success [32]. There is a critical need to determine if vascular dysfunction occurs in these horses so that our understanding of this disease can be enhanced.

In this study we aimed to characterise the function of small resistance vessels of the hoof, as well as remote systemic arteries of the facial skin, in healthy horses and those with EL. Though much of the human and rodent work investigating vascular function focusses on arteries, there is some evidence that, in laminitis, the laminar veins are differentially affected [33]. For this reason, we chose to include laminar veins in our study. Given that there are recognised differences between vascular beds in response to vasoactive mediators we chose to compare remote arteries of the facial skin.

In this study, therefore, we address the hypothesis that vascular dysfunction, specifically endothelial dysfunction, is a feature of EL and is not confined just to the vessels of the hoof.

Materials and Methods


This study was approved by the University of Edinburgh Veterinary Ethics and Research Committee (VERC 7014). Horses with chronic laminitis due to metabolic syndrome (EMS) or pituitary pars intermedia dysfunction (PPID), and healthy controls, destined for euthanasia, were recruited from clinics at the Royal (Dick) School of Veterinary Studies. All groups included females and castrated males, reflecting the clinical population in the UK. The age, breed, sex, body condition score (out of 5, a measure of obesity) [34], clinical features of previous laminitis (abnormal hoof growth) and medical history (specifically history of laminitis and glucocorticoid administration) were recorded. Blood was obtained after overnight fasting, between 0900h and 1100h, via an intravenous cannula inserted in the jugular vein for the purpose of euthanasia. ACTH, cortisol, and insulin concentrations were measured by chemiluminescent immunoassays validated for clinical use in the horse (Immulite 2000, Siemens, Camberley, UK) [35, 36]. Plasma triglycerides and glucose were measured using a colorimetric method based on the modified Jaffe’s reaction (IL650 analyser, Instrumentation Laboratories, Barcelona, Spain).

Horses were humanely euthanased with intravenous quinalbarbitone sodium and cinchocaine hydrochloride (1mL/10Kg bodyweight; Somulose, Dechra Veterinary Products, Shrewsbury, UK).

Tissue Preparation

Immediately following euthanasia tissue was harvested from the dorsal hoof and facial skin. The tissue was kept in physiological saline solution (PSS) at 4°C during dissection. Subcutaneous facial skin arteries (50–100μm in diameter) and laminar arteries and veins (100–500μm in diameter) were dissected from the tissue [37].

Small Vessel Wire Myography

The vessels were divided into 2mm sections and stored overnight in PSS. Vessels were mounted on intraluminal wires in myography baths containing PSS maintained at 37°C and perfused with 95% O2/5%CO2 [37]. A minimum of 4 sections of each vessel were collected from each horse. Once mounted two sections of laminar arteries, laminar veins and facial arteries from each horse had the endothelium removed by rubbing the luminal surface with a small wire. Each vessel underwent an equilibration period at an initial tension of 4 mN for arteries and 2 mN for veins for 1 hour [37]. Vessel viability was assessed using three consecutive stimulations with 125 mM potassium physiological saline solution (KPSS) followed by a washout period. Cumulative concentration-response curves for each vessel were then obtained for phenylephrine (1x10-9 – 1x10-4 M) and 5-hydroxytryptamine (5HT) (1x10-9 – 1x10-4 M). All drugs were dissolved in PSS. Following contraction with sufficient phenylephrine to produce 80% of the KPSS response (3x 10−7 M), a cumulative concentration-response curve was obtained for acetylcholine (1x10-9 – 1x10-4 M).

Statistical Analysis

Data reported are mean ± SEM. Contractions are expressed as force per unit length (mN/mm) and as a percentage of maximum KPSS-induced contraction, the maximal contraction (Emax) is reported for each agonist. Relaxation is expressed as percentage of pre-contraction with phenylephrine. Results from the two sections of each vessel type were averaged for further analysis. Sigmoid curves were fitted to the cumulative concentration-response data, 4 parameter logistic modelling performed. Data were tested for normality using a Kolmogorov-Smirnov test. Sensitivity to agonists is expressed as -log EC50 (pD2) for constrictors or -log IC50 for acetylcholine. The curves were analysed by 2-way ANOVA and post-hoc Tukey test. Comparisons of the group means was performed using Student’s unpaired t-test or Mann-Whitney U test following normality testing. Graphpad Prism 4 and SPSS were used for all statistical testing. Significance was defined at P<0.05.



Six healthy horses, with no history of laminitis and 6 horses with chronic EL (4 with EMS and 2 with PPID) were included in the study. The healthy group consisted of 4 castrated males and 2 non-pregnant females. The EL group consisted of 3 castrated males and 3 non-pregnant females. Horses in the EL group were not suffering from acute laminitis at the time of euthanasia. None of the animals had a history of glucocorticoid administration in the previous month. Clinical and biochemical characteristics are given in Table 1. Horses with EL had higher resting serum insulin and triglyceride concentrations and high body condition scores (obesity) compared with healthy horses.

Table 1. Clinical and biochemical characteristics of the study groups; healthy and those with endocrinopathic laminitis (EL).

Response of intact vessels from healthy horses to vasoconstrictors

Laminar arteries and veins and facial arteries from healthy horses contracted in response to KPSS, phenylephrine and 5HT (Table 2, Figs 1 and 2). Laminar arteries produced a greater contraction than facial skin arteries which produced a much greater contraction than laminar veins for all vasoconstrictors (Table 2). Laminar veins were more sensitive to 5HT than either laminar arteries or facial skin arteries (P = 0.02), this was endothelium-dependent.

Table 2. Response of intact vessels from healthy horses and horses with endocrinopathic laminitis (EL) to vasoconstrictors.

Fig 1. Cumulative concentration response curves to phenylephrine (PE) of intact [A] laminar arteries, [B] laminar veins and [C] facial skin arteries from healthy horses (●, n = 6) and horses with endocrinopathic laminitis (○, n = 6).

Data are expressed as a percentage of maximal contraction in response to high potassium saline (KPSS). Data are mean ± SEM. Curves were compared using two-way ANOVA. *P<0.05. The veins from horses with EL had larger maximal contractions in response to PE compared to healthy horses.

Fig 2. Cumulative concentration response curves to 5-hydroxytryptamine (5HT) of intact [A] laminar arteries, [B] laminar veins and [C] facial skin arteries from healthy horses (●, n = 6) and horses with endocrinopathic laminitis (○, n = 6).

Data are expressed as a percentage of maximal contraction in response to high potassium saline (KPSS). Data are mean ± SEM. Curves were compared using two-way ANOVA. *P<0.05. The veins from horses with EL had larger maximal contractions in response to 5HT compared to healthy horses.

Response of intact vessels from healthy horses to acetylcholine

All intact vessels relaxed in response to acetylcholine (Table 3; Fig 3) with the biggest response (as a percentage of phenylephrine pre-contraction) in laminar arteries (>>laminar veins = facial skin arteries; P = 0.02). Maximal relaxation in response to acetylcholine in laminar arteries was consistently greater than baseline tension (i.e. > 100% relaxation).

Table 3. Response of intact vessels from healthy horses and horses with endocrinopathic laminitis (EL) to acetylcholine following pre-contraction with phenylephrine.

Fig 3. Cumulative concentration response curves to acetylcholine (ACh) of intact [A] laminar arteries, [B] laminar veins and [C] facial skin arteries from healthy horses (●, n = 6) and horses with endocrinopathic laminitis (○, n = 6).

The horizontal line indicates baseline values prior to contraction with phenylephrine. Data are expressed as a percentage of maximal contraction in response to high potassium saline (KPSS). Data are mean ± SEM. Curves were compared using two-way ANOVA. *P<0.05, **P<0.005. Laminar arteries, veins and facial skin arteries of horses with EL relaxed significantly less than those from healthy horses.

Removal of the endothelium from vessels of healthy horses

Removal of the endothelium abolished acetylcholine-induced relaxation in all vessels. Denuding did not alter the magnitude of contraction in response to phenylephrine or 5HT; however, the sensitivity of denuded laminar veins (but not laminar or facial skin arteries) to phenylephrine (P = 0.004) and 5HT (P = 0.0004) was decreased (Table 4, Figs 4 and 5).

Table 4. Response of denuded vessels from healthy horses and horses with endocrinopathic laminitis (EL) to vasoconstrictors high potassium saline (KPSS), phenylephrine (PE) and 5-hydroxytryptamine (5HT).

Fig 4. Cumulative concentration response curves to phenylephrine (PE) of denuded [A] laminar arteries, [B] laminar veins and [C] facial skin arteries from healthy horses (●, n = 6) and horses with endocrinopathic laminitis (○, n = 6).

Data are expressed as a percentage of maximal contraction in response to high potassium saline (KPSS). Data are mean ± SEM. Curves were compared using two-way ANOVA. *P<0.05. There were no significant differences between healthy horses and those with EL.

Fig 5. Cumulative concentration response curves to 5-hydroxytryptamine (5HT) of denuded [A] laminar arteries, [B] laminar veins and [C] facial skin arteries from healthy horses (●, n = 6) and horses with endocrinopathic laminitis (○, n = 6).

Data are expressed as a percentage of maximal contraction in response to high potassium saline (KPSS). Data are mean ± SEM. Curves were compared using two-way ANOVA. *P<0.05. There were no significant differences between healthy horses and those with EL.

Vascular function in healthy horses compared to those with endocrinopathic laminitis

In comparison with healthy controls, acetylcholine-induced relaxation (Emax) was dramatically reduced in all vessels from horses with EL (Table 3; Fig 2). In addition, contractile responses (Emax mN/mm) to phenylephrine (P = 0.005) and 5HT (P = 0.0007) were increased in laminar veins from horses with EL (Table 2, Figs 1 and 2). Sensitivity to phenylephrine was reduced in laminar arteries (P = 0.006) and laminar veins (P = 0.009) from horses with EL (Table 2, Figs 1 and 2), this was an endothelium-independent effect in laminar arteries but not veins in which sensitivity was not significantly different when the veins were denuded.


The work presented here demonstrates that horses with endocrinopathic laminitis (EL) have vascular dysfunction manifest as blunting of endothelium-dependent vasodilation. This dysfunction is present in both the laminar vascular bed and distant facial skin arteries. In addition, laminar veins of EL horses showed further dysfunction with increased contractile responses to phenylephrine and 5HT, accompanied by a decrease in sensitivity to phenylephrine.

The vascular pathology associated with laminitis has been of interest for many years. Although there are reports of vascular dysfunction following experimentally induced inflammatory laminitis [38] there are no data pertaining to vascular dysfunction, local or systemic, in horses with EL, most likely due to the difficulties in obtaining samples from clinical cases. To assess vasoconstrictor function we used phenylephrine, an alpha-adrenoceptor agonist which produces stable and reliable concentration-dependent contractions of physiological relevance. Moreover, in treatment of laminitis alpha-adrenoceptor antagonists (e.g. acepromazine) are used clinically in an attempt to induce vasodilation [39]; phenylephrine is, therefore, also of pharmacological relevance in this disease. All three vessel types contracted in response to phenylephrine with both laminar and facial skin arteries having larger contractions than laminar veins. 5HT was used as an alternative contractile agonist in this study and elicited reproducible contractions of a similar magnitude to those induced by phenylephrine in all vessels. The response of equine vessels to 5HT has been a source of interest as both large and small equine veins are more sensitive to its effects than arteries [33, 40]. This has been proposed as a possible contributing factor to venous dysfunction in inflammatory laminitis in which circulating 5HT concentrations are elevated [38, 40], although elevated 5HT concentrations have not been demonstrated in EL. This differential sensitivity was replicated in our study. This differential sensitvity was endothelium-dependent consistent with other studies showing the response to 5HT is reliant on endothelial-derived nitric oxide [41]. Interestingly, while 5HT has been found to be significantly more potent in the larger palmer digital vessels compared to large facial arteries [40] there was no difference in sensitivity to this agent between small laminar arteries and small facial skin arteries.

Acetylcholine is commonly used in vascular function studies to induce endothelium-dependent relaxation via nitric oxide release [42]. As in other species, acetylcholine-mediated relaxation was endothelium-dependent in all vessels in this study. In contrast to the only other report of equine laminar vessel response to acetylcholine [43], laminar arteries in this study relaxed to greater than 200% of baseline tension in healthy horses. This is an unusual response in an isometric system, in which vessels do not normally develop tone unless stimulated, and is rarely observed in rodent vessels [42]. Some resistance vessels such as cerebral arteries exhibit myogenic tone in isometric systems [44], contracting in response to initial stretching without the addition of vasoconstrictors. The vessels in this study did not contract in response to application of baseline tension, indicating that myogenic tone did not develop. However, their response to acetylcholine implies that some degree of intrinsic tone is present in these vessels prior to application of baseline tension [45]. Intrinsic tone is normally a pathological response of vessels to high pressures; for example, in the context of pulmonary or renal hypertension [45]. The development of intrinsic tone in disease is usually accounted for by alterations in the mechanisms sensing or transducing a pressure stimulus, changes in shear wall stress or impaired endothelial function [46]. It is possible that laminar vessels have intrinsic tone as a normal physiological response to the much greater pressures they encounter than equivalent vessels in other species (capillary pressure in the standing horse’s hoof is approximately 35-50mmHg, compared to 20mmHg in the human foot and 15mmHg in the canine hind paw) [4749]. However, given that intrinsic tone appears also to be a feature of facial skin arteries it is unlikely to be explained by elevated perfusion pressure and may be a species-specific finding. It is important to note that, even though vessels from EL horses relaxed significantly less than those from healthy horses, the arteries still relaxed by 100% whereas the mean relaxation of the veins was only 70%. This most likely reflects endothelial dysfunction of the veins but, in the arteries, a loss of intrinsic tone may also play a role.

Inflammatory laminitis, induced with administration of black walnut extract, is known to result in failure of larger conduit vessels of the equine limb to adequately dilate in response to acetylcholine but the mechanism is unknown [50]. These experimental models are comparable to sepsis and multi organ failure in humans in which endothelial cell dysfunction is an important feature [51]. This is the first study to demonstrate similar vascular dysfunction in EL though systemic hypertension has been reported in ponies with insulin resistance [52] but whether this is due to vascular dysfunction is unknown. EL is associated with either EMS or PPID; these conditions have several features in common which may explain the evident vascular dysfunction. Both diseases are associated with insulin dysregulation, abnormal adiposity and probable cortisol dysregulation [53].

In this study all of the horses with EL had insulin dysregulation manifest as fasting hyperinsulinaemia. Hyperinsulinaemia can result in endothelial cell dysfunction, specifically blunting vasodilatory responses, as well as endothelial resistance to insulin- induced enhancement of vasodilation [54]. Insulin resistance results in a downregulation of the PI3kinase pathway with a subsequent reduction in NO production whilst the compensatory hyperinsulinemia causes excessive stimulation of the MAP Kinase pathway and production of ET-1 and reactive oxygen species in humans [55]. Ex vivo models of equine vessels incubated in high concentrations of insulin have shown that a similar phenomenon may also occur in horses [56] and this pathophysiological process may contribute to the endothelial dysfunction evident in this study.

The role of cortisol dysregulation in vascular function is less well defined as it is often difficult to distinguish the effects of hypercortisolaemia from the accompanying metabolic syndrome in humans. Human Cushing’s disease patients treated with surgery remain at high risk of cardiovascular disease years after the hypercortisolaemia has abated, most probably due to the persistence of features of metabolic syndrome [57]. However, human Cushing’s patients also show increased insulin-stimulated endothelin release which is not a feature of metabolic syndrome alone [58]. While EMS and PPID are not associated with hypercortisolaemia there is evidence of peripheral cortisol dysfunction in chronic laminitis which deserves further study [59]. Cortisol inhibits endothelial-dependent cholinergic vasodilation in humans most likely through an inhibition of NO synthesis [17], reduces the bioavailability of NO in vessels [60], inhibits tetrahydrobiopterin [61, 62], the cofactor necessary for maximal activity of nitric oxide synthase and potentiates the effects of vasoconstrictors [18, 63].

Expanding adipose tissue adopts a pro-inflammatory phenotype accompanied by increased production of reactive oxygen species. Obesity is associated with an uncoupling of eNOS, such that it produces superoxide ion (O2-) rather than NO, an event known to precede the establishment of other obesity co-morbidities [64]. A pro-inflammatory phenotype has been demonstrated in horses with insulin resistance and obesity [65, 66] but it has yet to be ascertained whether this is accompanied by dysregulation of NO.

Laminar veins showed more evidence of dysfunction in EL horses in this study compared with laminar and facial skin arteries. Veins are rarely studied in rodent models of vascular dysfunction or in human disease but have been shown to have altered function in experimentally-induced inflammatory models of laminitis in the horse [38, 67]. There are differences in the mechanism of response to vasoconstrictors between laminar arteries and veins. For example unlike arteries, laminar veins still contract in response to phenylephrine and 5HT when there is no extracellular calcium present [68]. Such mechanistic differences may go some way to explain the apparent preferential dysfunction of veins in disease. The venous return from the hoof relies on adequate relaxation of the veins and the pump action of the hoof hitting the ground [69]. Adequate venous return is essential to prevent elevation in capillary pressure and oedema. Reduced relaxation of the veins in disease may be of equal, if not more, importance than arterial dysfunction in the pathophysiology of EL and warrants further investigation.

It is important to note that the dysfunction identified in this study could be a cause or a consequence of disease. Failure of the vessels within the hoof to adequately dilate will have significant consequences, potentially reducing overall blood flow and reducing venous return. Such abnormalities may lead to increased capillary pressure and oedema and hypoxia of the laminar tissue. Equally systemic endothelial dysfunction may render these animals susceptible to other vascular and microvascular abnormalities such as retinal vascular lesions [70] not previously investigated in this population. Clinical vascular markers of endothelial dysfunction such as flow mediated dilatation may not be readily transferrable to equine medicine. However, plasma biomarkers of endothelial dysfunction, such as asymmetrical dimethylarginine and oxidized LDL [71], would be an invaluable clinical tool for determining laminitic risk and monitoring response to treatment. It is plausible that abrogating endothelial dysfunction may be beneficial in horses with EL in order to prevent or manage laminitis. Pharmacological interventions aimed at restoring blood flow to the hoof by alpha adrenoceptor antagonism (acepromazine, domperidone) or beta-adrenoceptor agonists (isoxsuprine hydrochloride) have been used clinically with varying success [39, 72], possibly reflecting our limited understanding of vascular dysfunction in laminitis. Given the high prevalence of this disorder and the clinical consequences there is still an urgent unmet clinical need in this area of veterinary medicine.

In conclusion, this study has shown endothelial dysfunction associated with EL affecting both laminar vessels and distant facial skin arteries. The endothelium may be a target for the treatment or diagnosis of EL.


The work was conducted in the University /BHF Centre for Cardiovascular Sciences. The authors are grateful to staff at the Royal (Dick) School of Veterinary Studies and the horse owners who participated in this study.

Author Contributions

  1. Conceptualization: RM JK PH BW.
  2. Formal analysis: RM PH.
  3. Funding acquisition: JK BW.
  4. Investigation: RM PH.
  5. Methodology: RM JK PH.
  6. Project administration: PH.
  7. Resources: PH JK.
  8. Supervision: PH BW.
  9. Validation: JK PH BW.
  10. Visualization: RM.
  11. Writing – original draft: RM PH JK.
  12. Writing – review & editing: RM PH JK BW.


  1. 1. Wylie CE, Collins SN, Verheyen KLP, Richard Newton J. Frequency of equine laminitis: A systematic review with quality appraisal of published evidence. Vet J. 2011;189(3):248–56. pmid:21665498
  2. 2. Karikoski NP, Horn I, McGowan TW, McGowan CM. The prevalence of endocrinopathic laminitis among horses presented for laminitis at a first-opinion/referral equine hospital. Domest Anim Endocrinol. 2011;41(3):111–7. pmid:21696910
  3. 3. Baldwin GI, Pollitt CC. Progression of Venographic Changes After Experimentally Induced Laminitis. Veterinary Clinics of North America—Equine Practice. 2010;26(1):135–40. pmid:20381742
  4. 4. Ackerman N, Garner HE, Coffman JR, Clement JW. Angiographic appearance of the normal equine foot and alterations in chronic laminitis. J Am Vet Med Assoc. 1975;166(1):58–62. Epub 1975/01/01. pmid:1110201.
  5. 5. Hunt RJ, Wharton RE. Clinical Presentation, Diagnosis, and Prognosis of Chronic Laminitis in North America. Veterinary Clinics of North America—Equine Practice. 2010;26(1):141–53. pmid:20381743
  6. 6. Walther G, Obert P, Dutheil F, Chapier R, Lesourd B, Naughton G, et al. Metabolic Syndrome Individuals With and Without Type 2 Diabetes Mellitus Present Generalized Vascular Dysfunction: Cross-Sectional Study. Arteriosclerosis, Thrombosis, and Vascular Biology. 2015. pmid:25657309
  7. 7. Iuchi T, Akaike M, Mitsui T, Ohshima Y, Shintani Y, Azuma H, et al. Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circulation Research. 2003;92(1):81–7. pmid:12522124
  8. 8. Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. Journal of Clinical Endocrinology and Metabolism. 2003;88(6):2527–33. pmid:12788849
  9. 9. Sima AV, Stancu CS, Simionescu M. Vascular endothelium in atherosclerosis. Cell Tissue Res. 2009;335(1):191–203. pmid:18797930
  10. 10. Walker BR, Soderberg S, Lindahl B, Olsson T. Independent effects of obesity and cortisol in predicting cardiovascular risk factors in men and women. J Intern Med. 2000;247(2):198–204. pmid:10692082
  11. 11. Brook RD, Bard RL, Glazewski L, Kehrer C, Bodary PF, Eitzman DL, et al. Effect of short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults. American Journal of Cardiology. 2004;93(8):1012–6. pmid:15081445
  12. 12. Balletshofer BM, Rittig K, Stock J, Lehn-Stefan A, Overkamp D, Dietz K, et al. Insulin resistant young subjects at risk of accelerated atherosclerosis exhibit a marked reduction in peripheral endothelial function early in life but not differences in intima-media thickness. Atherosclerosis. 2003;171(2):303–9. pmid:14644401
  13. 13. Arcaro G, Cretti A, Balzano S, Lechi A, Muggeo M, Bonora E, et al. Insulin causes endothelial dysfunction in humans: Sites and mechanisms. Circulation. 2002;105(5):576–82. pmid:11827922
  14. 14. Arcaro G, Zamboni M, Rossi L, Turcato E, Covi G, Armellini F, et al. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. International Journal of Obesity. 1999;23(9):936–42. pmid:10490799
  15. 15. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation. 2002;105(7):804–9. pmid:11854119
  16. 16. Rodríguez-Pérez JC, Rodríguez-Esparragón F, Hernández-Perera O, Anabitarte A, Losada A, Medina A, et al. Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol. 2001;37(6):1523–8. pmid:11345360
  17. 17. Mangos GJ, Walker BR, Kelly JJ, Lawson JA, Webb DJ, Whitworth JA. Cortisol inhibits cholinergic vasodilatation in the human forearm. American Journal of Hypertension. 2000;13(11):1155–60. Cited By (since 1996) 70 Export Date 17 April 2012. pmid:11078174
  18. 18. Walker BR, Best R, Shackleton CHL, Padfield PL, Edwards CRW. Increased vasoconstrictor sensitivity to glucocorticoids in essential hypertension. Hypertension. 1996;27(2):190–6. pmid:8567040
  19. 19. Hadoke PW, Iqbal J, Walker BR. Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. Br J Pharmacol. 2009;156(5):689–712. pmid:19239478; PubMed Central PMCID: PMC2551674.
  20. 20. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Annals of Internal Medicine. 2004;141(10):764–70. pmid:15545676
  21. 21. Baykan M, Erem C, Gedikli Ö, Hacihasanoglu A, Erdogan T, Kocak M, et al. Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushing's Syndrome. Endocrine. 2007;31(3):300–4. pmid:17906379
  22. 22. Matsunaga T, Okumura K, Ishizaka H, Tsunoda R, Tayama S, Tabuchi T, et al. Impairment of coronary blood flow regulation by endothelium-derived nitric oxide in dogs with alloxan-induced diabetes. Journal of Cardiovascular Pharmacology. 1996;28(1):60–7. pmid:8797137
  23. 23. Eichhorn B, Muller G, Leuner A, Sawamura T, Ravens U, Morawietz H. Impaired vascular function in small resistance arteries of LOX-1 overexpressing mice on high-fat diet. Cardiovascular Research. 2009;82(3):493–502. pmid:19289377
  24. 24. Morgan RA, McGowan TW, McGowan CM. Prevalence and risk factors for hyperinsulinaemia in ponies in Queensland, Australia. Australian Vet J. 2014;92(4):101–6. pmid:24673135
  25. 25. Karikoski NP, Patterson-Kane JC, Singer ER, McFarlane D, McGowan CM. Lamellar pathology in horses with pituitary pars intermedia dysfunction (PPID). Equine Vet J. 2015; In Press. pmid:25869529
  26. 26. McGowan CM, Frost R, Pfeiffer DU, Neiger R. Serum insulin concentrations in horses with equine Cushing's syndrome: Response to a cortisol inhibitor and prognostic value. Equine Vet J. 2004;36(3):295–8. pmid:15147141
  27. 27. Asplin KE, Sillence MN, Pollitt CC, McGowan CM. Induction of laminitis by prolonged hyperinsulinaemia in clinically normal ponies. Vet J. 2007;174(3):530–5. Cited By (since 1996) 69 Export Date 16 April 2012. pmid:17719811
  28. 28. Carter RA, Treiber KH, Geor RJ, Douglass L, Harris PA. Prediction of incipient pasture-associated laminitis from hyperinsulinaemia, hyperleptinaemia and generalised and localised obesity in a cohort of ponies. Equine Vet J. 2009;41(2):171–8. pmid:19418747
  29. 29. Wylie CE, Collins SN, Verheyen KLP, Newton JR. Risk factors for equine laminitis: A case-control study conducted in veterinary-registered horses and ponies in Great Britain between 2009 and 2011. Vet J. 2013;198(1):57–69. pmid:24070987
  30. 30. Cornelisse CJ, Robinson NE. Glucocorticoid therapy and the risk of equine laminitis. Equine Veterinary Education. 2013;25(1):39–46.
  31. 31. Keen JA, McGorum BC, Hillier C, Nally JE. Short-term incubation of equine laminar veins with cortisol and insulin alters contractility in vitro: Possible implications for the pathogenesis of equine laminitis. J Vet Pharmacol Ther. 2012;36(4):382–8. pmid:22943152
  32. 32. Bailey SR, Elliott J. The role of prostanoids and nitric oxide in endotoxin-induced hyporesponsiveness of equine digital blood vessels. Equine Vet J. 1999;31(3):212–8. Epub 1999/07/13. pmid:10402134.
  33. 33. Peroni JF, Moore JN, Noschka E, Grafton ME, Aceves-Avila M, Lewis SJ, et al. Predisposition for venoconstriction in the equine laminar dermis: implications in equine laminitis. Journal of applied physiology (Bethesda, Md: 1985). 2006;100(3):759–63. Epub 2005/11/05. pmid:16269525.
  34. 34. Carroll CL, Huntington PJ. Body condition scoring and weight estimation of horses. Equine Vet J. 1988;20(1):41–5. pmid:3366105
  35. 35. Perkins GA, Lamb S, Erb HN, Schanbacher B, Nydam DV, Divers TJ. Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide. Equine Veterinary Journal. 2002;34(7):679–85. pmid:12455838
  36. 36. McGowan T, Geor R, Evans H. Comparison of 4 assays for serum insulin analysis in the horse. ACVIM Forum, Texas. 2008; (Journal Article).
  37. 37. Keen JA, Hillier C, McGorum BC, Bunton D, Nally JE. Evaluation of Equine Laminar Vein Function: Harvesting, dissection and the use of functional methods to distinguish between veins and arteries. J Pharmacol Toxicol Methods. 2008;57(2):92–9. pmid:18280185
  38. 38. Peroni JF, Harrison WE, Moore JN, Graves JE, Lewis SJ, Krunkosky TM, et al. Black walnut extract-induced laminitis in horses is associated with heterogeneous dysfunction of the laminar microvasculature. Equine Vet J. 2005;37(6):546–51. Epub 2005/11/22. pmid:16295933.
  39. 39. Adair Iii HS, Schmidhammer JL, Goble DO, Green EM, Rivera-Walker C. Effects of acepromazine maleate, isoxsuprine hydrochloride and prazosin hydrochloride on laminar microcirculatory blood flow in healthy horses. Journal of Equine Veterinary Science. 1997;17(11):599–603.
  40. 40. Bailey SR, Elliott J. Plasma 5-hydroxytryptamine constricts equine digital blood vessels in vitro: implications for pathogenesis of acute laminitis. Equine Vet J. 1998;30(2):124–30. Epub 1998/04/16. pmid:9535068.
  41. 41. Berhane Y, Elliott J, Bailey SR. Assessment of endothelium-dependent vasodilation in equine digital resistance vessels. J Vet Pharmacol Ther. 2006;29(5):387–95. Epub 2006/09/09. pmid:16958783.
  42. 42. White RM, Rivera CO, Davison CB. Differential contribution of endothelial function to vascular reactivity in conduit and resistance arteries from deoxycorticosterone-salt hypertensive rats. Hypertension. 1996;27(6):1245–53. pmid:8641731
  43. 43. Wooldridge AA, Waguespack RW, Schwartz DD, Venugopal CS, Eades SC, Beadle RE. Vasorelaxation responses to insulin in laminar vessel rings from healthy, lean horses. Vet J. 2014;202(1):83–8. pmid:25155219
  44. 44. Izzard AS, Heagerty AM. Myogenic properties of brain and cardiac vessels and their relation to disease. Current Vascular Pharmacology. 2014;12(6):829–35. pmid:24066936
  45. 45. Martinez-Lemus LA, Hester RK, Becker EJ, Jeffrey JS, Odom TW. Pulmonary artery endothelium-dependent vasodilation is impaired in a chicken model of pulmonary hypertension. American Journal of Physiology—Regulatory Integrative and Comparative Physiology. 1999;277(1 46–1):R190–R7. pmid:10409273
  46. 46. Dunn WR, Wallis SJ, Gardiner SM. Remodelling and enhanced myogenic tone in cerebral resistance arteries isolated from genetically hypertensive brattleboro rats. Journal of Vascular Research. 1998;35(1):18–26. pmid:9482692
  47. 47. Chen HI, Granger HJ, Taylor AE. Interaction of capillary, interstitial, and lymphatic forces in the canine hindpaw. Circulation Research. 1976;39(2):245–54. pmid:939010
  48. 48. De Graaff JC, Ubbink DT, Van der Spruit JA, Lagarde SM, Jacobs MJHM. Influence of peripheral arterial disease on capillary pressure in the foot. Journal of Vascular Surgery. 2003;38(5):1067–74. pmid:14603219
  49. 49. Ratzlaff MH, Shindell RM, DeBowes RM. Changes in digital venous pressures of horses moving at the walk and trot. American Journal of Veterinary Research. 1985;46(7):1545–9. pmid:4026037
  50. 50. Schneider DA, Parks AH, Eades SC, Tackett RL. Palmar digital vessel relaxation in healthy horses and in horses given carbohydrate. American Journal of Veterinary Research. 1999;60(2):233–9. Cited By (since 1996) 18 Export Date 16 April 2012. pmid:10048558
  51. 51. Szabo C, Goldstein B. Endothelial dysfunction as predictor of mortality in sepsis. Critical Care Medicine. 2011;39(4):878–9. pmid:21613831
  52. 52. Bailey SR, Habershon-Butcher JL, Ransom KJ, Elliott J, Menzies-Gow NJ. Hypertension and insulin resistance in a mixed-breed population of ponies predisposed to laminitis. American Journal of Veterinary Research. 2008;69(1):122–9. pmid:18167097
  53. 53. Johnson PJ, Messer NT, Ganjam VK. Cushing's syndromes, insulin resistance and endocrinopathic laminitis. Equine Vet J. 2004;36(3):194–8. pmid:15147123
  54. 54. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. Journal of Clinical Investigation. 1996;97(11):2601–10. pmid:8647954
  55. 55. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. Journal of Clinical Investigation. 2000;105(3):311–20. pmid:10675357
  56. 56. Venugopal CS, Eades S, Holmes EP, Beadle RE. Insulin resistance in equine digital vessel rings: An in vitro model to study vascular dysfunction in equine laminitis. Equine Vet J. 2011;43(6):744–9. pmid:21496102
  57. 57. Geer EB, Shen W, Strohmayer E, Post KD, Freda PU. Body composition and cardiovascular risk markers after remission of Cushing's Disease: A prospective study using whole-body MRI. Journal of Clinical Endocrinology and Metabolism. 2012;97(5):1702–11. pmid:22419708
  58. 58. Setola E, Losa M, Lanzi R, Lucotti P, Monti LD, Castrignanò T, et al. Increased insulin-stimulated endothelin-1 release is a distinct vascular phenotype distinguishing Cushing's disease from metabolic syndrome. Clinical Endocrinology. 2007;66(4):586–92. pmid:17371479
  59. 59. Johnson PJ, Ganjam VK, Slight SH, Kreeger JM, Messer NT. Tissue-specific dysregulation of cortisol metabolism in equine laminitis. Equine Vet J. 2004;36(1):41–5. Epub 2004/02/06. pmid:14756370.
  60. 60. Wallerath T, Witte K, Schäfer SC, Schwarz PM, Prellwitz W, Wohlfart P, et al. Down-regulation of the expression of endothelial NO synthase is likely to contribute to qlucocorticoid-mediated hypertension. Proc Natl Acad Sci U S A. 1999;96(23):13357–62. Cited By (since 1996) 143 Export Date 17 April 2012. pmid:10557325
  61. 61. Axelrod L. Inhibition of prostacyclin production mediates permissive effect of glucocorticoids on vascular tone. Perturbations of the mechanism contribute to pathogenesis of Cushing's syndrome and Addison's disease. Lancet. 1983;1(8330):904–6. pmid:6132223
  62. 62. Hattori Y, Akimoto K, Nakanishi N, Kasai K. Glucocorticoid regulation of nitric oxide and tetrahydrobiopterin in a rat model of endotoxic shock. Biochemical and Biophysical Research Communications. 1997;240(2):298–303. pmid:9388472
  63. 63. Whitworth JA, Connel JMC, Gordon D, Scoggins BA. Effects of indomethacin on steroid-induced changes in pressor responsiveness in man. Clinical and Experimental Pharmacology and Physiology. 1988;15(4):305–10. pmid:3271611
  64. 64. Lobato NS, Filgueira FP, Akamine EH, Davel APC, Rossoni LV, Tostes RC, et al. Obesity induced by neonatal treatment with monosodium glutamate impairs microvascular reactivity in adult rats: Role of NO and prostanoids. Nutr Metab Cardiovasc Dis. 2011;21(10):808–16. pmid:20554176
  65. 65. Burns TA, Geor RJ, Mudge MC, McCutcheon LJ, Hinchcliff KW, Belknap JK. Proinflammatory cytokine and chemokine gene expression profiles in subcutaneous and visceral adipose tissue depots of insulin-resistant and insulin-sensitive light breed horses. Journal of Veterinary Internal Medicine. 2010;24(4):932–9. pmid:20649750
  66. 66. Adams AA, Katepalli MP, Kohler K, Reedy SE, Stilz JP, Vick MM, et al. Effect of body condition, body weight and adiposity on inflammatory cytokine responses in old horses. Vet Immunol Immunopathol. 2009;127(3–4):286–94. pmid:19097648
  67. 67. Eaton SA, Allen D, Eades SC, Schneider DA. Digital Starling forces and hemodynamics during early laminitis induced by an aqueous extract of black walnut (Juglans nigra) in horses. American Journal of Veterinary Research. 1995;56(10):1338–44. pmid:8928952
  68. 68. Peroni JF, Moore JN, Noschka E, Lewis TH, Lewis SJ, Roberston TP. Effect of voltage-gated and capacitative calcium entry blockade on agonist-induced constriction of equine laminar blood vessels. American Journal of Veterinary Research. 2007;68(7):722–9. pmid:17605607
  69. 69. Allen D Jr, Korthuis RJ, Clark S. Evaluation of starling forces in the equine digit. Journal of Applied Physiology. 1988;64(4):1580–3. pmid:3378993
  70. 70. Gkaliagkousi E, Gavriilaki E, Triantafyllou A, Douma S. Clinical Significance of Endothelial Dysfunction in Essential Hypertension. Current Hypertension Reports. 2015;17(11):85. pmid:26371063
  71. 71. Lekakis J, Abraham P, Balbarini A, Blann A, Boulanger CM, Cockcroft J, et al. Methods for evaluating endothelial function: A position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Prev Rehabil. 2011;18(6):775–89. pmid:21450600
  72. 72. Castro JR, Adair HS 3rd, Radecki SV, Kiefer VR, Elliot SB, Longhofer SL. Effects of domperidone on digital laminar microvascular blood flow in clinically normal adult horses. Am J Vet Res. 2010;71(3):281–7. Epub 2010/03/02. pmid:20187829.